FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2088377303> ?p ?o ?g. }

• W2088377303 endingPage "2737" @default.
• W2088377303 startingPage "2737" @default.
• W2088377303 abstract "Abstract [Background] Metformin has a potential to inhibit tumor growth in various cancer cell lines in vitro and in vivo. [Purpose] To elucidate anti-proliferative actions of the agent on various types of human lung cancer cell lines, and to evaluate combined effects with cisplatin. [Methods] Cell lines used consisted of four human lung cancer cell lines, RERF-LC-AI (squamous cell carcinoma), A549 (adenocarcinoma), IA-5 (large cell carcinoma) and WA-hT (small cell carcinoma). Colonogenic assay was employed to evaluate colonogenicity with exposure to metformin for 1, 24 hours and 10 days. In cell surviving assay, 100,000 cells per plate were cultured for 4 days with metformin and/or cisplatin, and survived cells were counted. [Results] Metformin inhibited colonogenecity in every cell line in a dose-dependent manner when cells were exposed to the agent for 10 days, whereas 1- and 24-hour exposure yielded not significant or only mild effects, with the degree varied depending on cell lines. With cell surviving assay at the metformin concentrations where 70% (IC70) and 30% (IC30) of the cells survived for each cell line, apoptosis was not increased over control groups in every cell line except for WA-hT that showed significant increase in apoptosis with metformin. Significant alteration in cell cycle distribution with the agent was not observed in all of the 4 cell lines. For evaluating combination treatment consisting of metformin and cisplatin, cisplatin at doses of IC50 and IC10 was combined with metformin. Inhibitory effects of metformin on cell proliferation were slightly suppressed with cisplatin at its dose of IC50 in all except for in A549. High dose (IC10) of cisplatin almost completely countervailed or even reversed the metformin effects in all cell lines, again except for A549 where a modest but significant sub-additive effect was observed. [Conclusions] Metformin has anti-proliferative effects on various types of human lung cancer cell lines. Although apoptosis was observed only in a small-cell lung cancer cell line, its effects may not depend on apoptosis in other 3 cell lines. Alteration of cell cycle distribution was not observed in all cell lines. Metformin and cisplatin were antagonistic especially with higher dose cisplatin. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2737. doi:1538-7445.AM2012-2737" @default.
• W2088377303 created "2016-06-24" @default.
• W2088377303 creator A5000377692 @default.
• W2088377303 creator A5005005279 @default.
• W2088377303 creator A5027496527 @default.
• W2088377303 creator A5027580659 @default.
• W2088377303 creator A5047891831 @default.
• W2088377303 creator A5052582907 @default.
• W2088377303 creator A5056703048 @default.
• W2088377303 creator A5060063956 @default.
• W2088377303 creator A5072537752 @default.
• W2088377303 creator A5081611023 @default.
• W2088377303 creator A5083778224 @default.
• W2088377303 date "2012-04-01" @default.
• W2088377303 modified "2023-09-27" @default.
• W2088377303 title "Abstract 2737: Anti-proliferative action of metformin on various types of human lung cancer cell lines" @default.
• W2088377303 doi "https://doi.org/10.1158/1538-7445.am2012-2737" @default.
• W2088377303 hasPublicationYear "2012" @default.
• W2088377303 type Work @default.
• W2088377303 sameAs 2088377303 @default.
• W2088377303 citedByCount "1" @default.
• W2088377303 countsByYear W20883773032023 @default.
• W2088377303 crossrefType "journal-article" @default.
• W2088377303 hasAuthorship W2088377303A5000377692 @default.
• W2088377303 hasAuthorship W2088377303A5005005279 @default.
• W2088377303 hasAuthorship W2088377303A5027496527 @default.
• W2088377303 hasAuthorship W2088377303A5027580659 @default.
• W2088377303 hasAuthorship W2088377303A5047891831 @default.
• W2088377303 hasAuthorship W2088377303A5052582907 @default.
• W2088377303 hasAuthorship W2088377303A5056703048 @default.
• W2088377303 hasAuthorship W2088377303A5060063956 @default.
• W2088377303 hasAuthorship W2088377303A5072537752 @default.
• W2088377303 hasAuthorship W2088377303A5081611023 @default.
• W2088377303 hasAuthorship W2088377303A5083778224 @default.
• W2088377303 hasConcept C121608353 @default.
• W2088377303 hasConcept C126322002 @default.
• W2088377303 hasConcept C134018914 @default.
• W2088377303 hasConcept C1491633281 @default.
• W2088377303 hasConcept C150903083 @default.
• W2088377303 hasConcept C190283241 @default.
• W2088377303 hasConcept C207001950 @default.
• W2088377303 hasConcept C2776694085 @default.
• W2088377303 hasConcept C2778239845 @default.
• W2088377303 hasConcept C2780323712 @default.
• W2088377303 hasConcept C29537977 @default.
• W2088377303 hasConcept C502942594 @default.
• W2088377303 hasConcept C54355233 @default.
• W2088377303 hasConcept C55493867 @default.
• W2088377303 hasConcept C555293320 @default.
• W2088377303 hasConcept C62112901 @default.
• W2088377303 hasConcept C71924100 @default.
• W2088377303 hasConcept C81885089 @default.
• W2088377303 hasConcept C86803240 @default.
• W2088377303 hasConcept C96232424 @default.
• W2088377303 hasConcept C98274493 @default.
• W2088377303 hasConceptScore W2088377303C121608353 @default.
• W2088377303 hasConceptScore W2088377303C126322002 @default.
• W2088377303 hasConceptScore W2088377303C134018914 @default.
• W2088377303 hasConceptScore W2088377303C1491633281 @default.
• W2088377303 hasConceptScore W2088377303C150903083 @default.
• W2088377303 hasConceptScore W2088377303C190283241 @default.
• W2088377303 hasConceptScore W2088377303C207001950 @default.
• W2088377303 hasConceptScore W2088377303C2776694085 @default.
• W2088377303 hasConceptScore W2088377303C2778239845 @default.
• W2088377303 hasConceptScore W2088377303C2780323712 @default.
• W2088377303 hasConceptScore W2088377303C29537977 @default.
• W2088377303 hasConceptScore W2088377303C502942594 @default.
• W2088377303 hasConceptScore W2088377303C54355233 @default.
• W2088377303 hasConceptScore W2088377303C55493867 @default.
• W2088377303 hasConceptScore W2088377303C555293320 @default.
• W2088377303 hasConceptScore W2088377303C62112901 @default.
• W2088377303 hasConceptScore W2088377303C71924100 @default.
• W2088377303 hasConceptScore W2088377303C81885089 @default.
• W2088377303 hasConceptScore W2088377303C86803240 @default.
• W2088377303 hasConceptScore W2088377303C96232424 @default.
• W2088377303 hasConceptScore W2088377303C98274493 @default.
• W2088377303 hasIssue "8_Supplement" @default.
• W2088377303 hasLocation W20883773031 @default.
• W2088377303 hasOpenAccess W2088377303 @default.
• W2088377303 hasPrimaryLocation W20883773031 @default.
• W2088377303 hasRelatedWork W1518035471 @default.
• W2088377303 hasRelatedWork W2030883789 @default.
• W2088377303 hasRelatedWork W2348182528 @default.
• W2088377303 hasRelatedWork W2350294409 @default.
• W2088377303 hasRelatedWork W2371312746 @default.
• W2088377303 hasRelatedWork W2372283855 @default.
• W2088377303 hasRelatedWork W2374592133 @default.
• W2088377303 hasRelatedWork W2378222954 @default.
• W2088377303 hasRelatedWork W2382230817 @default.
• W2088377303 hasRelatedWork W2387175565 @default.
• W2088377303 hasVolume "72" @default.
• W2088377303 isParatext "false" @default.
• W2088377303 isRetracted "false" @default.
• W2088377303 magId "2088377303" @default.
• W2088377303 workType "article" @default.